Compositions and methods using reelin in alzheimer's disease

Administering reelin proteins or nucleic acids with specific mutations addresses the ineffectiveness of current Alzheimer's treatments by enhancing reelin signaling and reducing tau pathology, thereby delaying cognitive decline and dementia.

US20260139017A1Pending Publication Date: 2026-05-21THE GENERAL HOSPITAL CORP +2
View PDF 0 Cites 0 Cited by

Patent Information

Authority / Receiving Office
US · United States
Patent Type
Applications(United States)
Current Assignee / Owner
THE GENERAL HOSPITAL CORP
Filing Date
2023-10-13
Publication Date
2026-05-21

Smart Images

  • Figure US20260139017A1-D00000_ABST
    Figure US20260139017A1-D00000_ABST
Patent Text Reader

Abstract

Described herein are methods and compositions for treating Alzheimer's Disease (AD), as well as compositions comprising a reelin-derived peptide and methods of use thereof.
Need to check novelty before this filing date? Find Prior Art